| | Business Summary | | ImClone
Systems,
Inc.
is
a
biopharmaceutical
company
that
is
developing
a
portfolio
of
targeted
biologic
treatments
designed
to
address
the
medical
needs
of
patients
with
a
variety
of
cancers.
The
Company
focuses
on
three
strategies
for
treating
cancer,
growth
factor
blockers,
cancer
vaccines
and
angiogenesis
inhibitors.
The
Company's
lead
product
candidate,
IMC-C225,
is
a
therapeutic
monoclonal
antibody
that
inhibits
stimulation
of
a
receptor
for
growth
factors
upon
which
certain
solid
tumors
depend
in
order
to
grow.
IMC-C225
has
been
shown
in
several
Phase
I/II
trials
to
have
an
acceptable
safety
profile,
to
be
well
tolerated
and,
when
administered
with
either
radiation
therapy
or
chemotherapy,
to
enhance
tumor
reduction. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | IMCL
is
a
biopharmaceutical
company
engaged
in
the
research
and
development
of
novel
cancer
treatments.
The
Co.
focuses
on
three
promising
strategies
for
treating
cancer:
growth
factor
inhibitors,
therapeutic
cancer
vaccines
and
angiogenesis
inhibitors.
For
the
six
months
ended
6/01,
revenues
totalled
$28
million,
up
from
$448
thousand.
Net
loss
before
accnt.
change
applicable
to
Com.
rose
13%
to
$30.7
million.
Results
reflect
increased
license
fees,
offset
by
higher
R&D
costs. | | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Robert Goldhammer, 69
Chairman | -- | Samuel Waksal, Ph.D., 52
Pres,
CEO, Director | $910K | Daniel Lynch
CFO, VP-Fin. | -- | Harlan Waksal, M.D., 47
Exec.
VP, COO | 750K | Ronald Martell, 38
VP,
Marketing | 275K | | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/i/imcl.gif)